These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 20921235)

  • 1. Lower levels of glutathione in the brains of secondary progressive multiple sclerosis patients measured by 1H magnetic resonance chemical shift imaging at 3 T.
    Choi IY; Lee SP; Denney DR; Lynch SG
    Mult Scler; 2011 Mar; 17(3):289-96. PubMed ID: 20921235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Longitudinal changes of cerebral glutathione (GSH) levels associated with the clinical course of disease progression in patients with secondary progressive multiple sclerosis.
    Choi IY; Lee P; Hughes AJ; Denney DR; Lynch SG
    Mult Scler; 2017 Jun; 23(7):956-962. PubMed ID: 27620894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo evidence of oxidative stress in brains of patients with progressive multiple sclerosis.
    Choi IY; Lee P; Adany P; Hughes AJ; Belliston S; Denney DR; Lynch SG
    Mult Scler; 2018 Jul; 24(8):1029-1038. PubMed ID: 28569645
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis.
    Abdel-Aziz K; Schneider T; Solanky BS; Yiannakas MC; Altmann DR; Wheeler-Kingshott CA; Peters AL; Day BL; Thompson AJ; Ciccarelli O
    Brain; 2015 Jun; 138(Pt 6):1568-82. PubMed ID: 25863355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Investigation of outer cortical magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups.
    Samson RS; Cardoso MJ; Muhlert N; Sethi V; Wheeler-Kingshott CA; Ron M; Ourselin S; Miller DH; Chard DT
    Mult Scler; 2014 Sep; 20(10):1322-30. PubMed ID: 24552746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary-progressive form of multiple sclerosis: MRI changes versus clinical status.
    Masek M; Vaneckova M; Krasensky J; Danes J; Havrdova E; Hrebikova T; Seidl Z
    Neuro Endocrinol Lett; 2008 Aug; 29(4):461-6. PubMed ID: 18766142
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinically benign multiple sclerosis despite large T2 lesion load: can we explain this paradox?
    Strasser-Fuchs S; Enzinger C; Ropele S; Wallner M; Fazekas F
    Mult Scler; 2008 Mar; 14(2):205-11. PubMed ID: 17986507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of endogenous antiradical protective system in multiple sclerosis.
    Davitashvili D; Beridze M; Shakarishvili R; Kiziria M; Sanikidze T
    Georgian Med News; 2012 Apr; (205):11-9. PubMed ID: 22665726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Beyond focal cortical lesions in MS: An in vivo quantitative and spatial imaging study at 7T.
    Louapre C; Govindarajan ST; Giannì C; Langkammer C; Sloane JA; Kinkel RP; Mainero C
    Neurology; 2015 Nov; 85(19):1702-9. PubMed ID: 26468411
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gray matter N-acetyl aspartate deficits in secondary progressive but not relapsing-remitting multiple sclerosis.
    Adalsteinsson E; Langer-Gould A; Homer RJ; Rao A; Sullivan EV; Lima CA; Pfefferbaum A; Atlas SW
    AJNR Am J Neuroradiol; 2003; 24(10):1941-5. PubMed ID: 14625214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cortical involvement determines impairment 30 years after a clinically isolated syndrome.
    Haider L; Prados F; Chung K; Goodkin O; Kanber B; Sudre C; Yiannakas M; Samson RS; Mangesius S; Thompson AJ; Gandini Wheeler-Kingshott CAM; Ciccarelli O; Chard DT; Barkhof F
    Brain; 2021 Jun; 144(5):1384-1395. PubMed ID: 33880511
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis.
    Kizlaitienė R; Kaubrys G; Giedraitienė N; Ramanauskas N; Dementavičienė J
    Med Sci Monit; 2017 Feb; 23():588-597. PubMed ID: 28145395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Brain oxidative stress: detection and mapping of anti-oxidant marker 'Glutathione' in different brain regions of healthy male/female, MCI and Alzheimer patients using non-invasive magnetic resonance spectroscopy.
    Mandal PK; Tripathi M; Sugunan S
    Biochem Biophys Res Commun; 2012 Jan; 417(1):43-8. PubMed ID: 22120629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gray matter atrophy in multiple sclerosis: a longitudinal study.
    Fisher E; Lee JC; Nakamura K; Rudick RA
    Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of cytotoxic Eomes-expressing CD4
    Raveney BJE; Sato W; Takewaki D; Zhang C; Kanazawa T; Lin Y; Okamoto T; Araki M; Kimura Y; Sato N; Sano T; Saito Y; Oki S; Yamamura T
    Proc Natl Acad Sci U S A; 2021 Mar; 118(11):. PubMed ID: 33836594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A magnetic resonance imaging voxel-based morphometry study of regional gray matter atrophy in patients with benign multiple sclerosis.
    Mesaros S; Rovaris M; Pagani E; Pulizzi A; Caputo D; Ghezzi A; Bertolotto A; Capra R; Falautano M; Martinelli V; Comi G; Filippi M
    Arch Neurol; 2008 Sep; 65(9):1223-30. PubMed ID: 18779427
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Doubly selective multiple quantum chemical shift imaging and T(1) relaxation time measurement of glutathione (GSH) in the human brain in vivo.
    Choi IY; Lee P
    NMR Biomed; 2013 Jan; 26(1):28-34. PubMed ID: 22730142
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MRI measures show significant cerebellar gray matter volume loss in multiple sclerosis and are associated with cerebellar dysfunction.
    Anderson VM; Fisniku LK; Altmann DR; Thompson AJ; Miller DH
    Mult Scler; 2009 Jul; 15(7):811-7. PubMed ID: 19465449
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predicting the severity of relapsing-remitting MS: the contribution of cross-sectional and short-term follow-up MRI data.
    Enzinger C; Fuchs S; Pichler A; Wallner-Blazek M; Khalil M; Langkammer C; Ropele S; Fazekas F
    Mult Scler; 2011 Jun; 17(6):695-701. PubMed ID: 21228028
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cerebral atrophy and disability in relapsing-remitting and secondary progressive multiple sclerosis over four years.
    Turner B; Lin X; Calmon G; Roberts N; Blumhardt LD
    Mult Scler; 2003 Feb; 9(1):21-7. PubMed ID: 12617263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.